Cargando…
Advances in Diagnosis and Therapy for Bladder Cancer
SIMPLE SUMMARY: The clinical management of bladder cancer has been developing in the past decade, including diagnostic tools and treatment options. Both monotherapy and combination therapy have been undoubtedly upgraded. Multiple diagnostic techniques and therapeutic strategies have been developed t...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265007/ https://www.ncbi.nlm.nih.gov/pubmed/35804953 http://dx.doi.org/10.3390/cancers14133181 |
_version_ | 1784743102474354688 |
---|---|
author | Hu, Xinzi Li, Guangzhi Wu, Song |
author_facet | Hu, Xinzi Li, Guangzhi Wu, Song |
author_sort | Hu, Xinzi |
collection | PubMed |
description | SIMPLE SUMMARY: The clinical management of bladder cancer has been developing in the past decade, including diagnostic tools and treatment options. Both monotherapy and combination therapy have been undoubtedly upgraded. Multiple diagnostic techniques and therapeutic strategies have been developed to meet the urgent clinical needs, resulting in the emergence of various explorations for cancer diagnosis and therapy. In this review, we mainly focus on the advances in the diagnosis and treatment of bladder cancer. ABSTRACT: Bladder cancer (BCa) is one of the most common and expensive urinary system malignancies for its high recurrence and progression rate. In recent years, immense amounts of studies have been carried out to bring a more comprehensive cognition and numerous promising clinic approaches for BCa therapy. The development of innovative enhanced cystoscopy techniques (optical techniques, imaging systems) and tumor biomarkers-based non-invasive urine screening (DNA methylation-based urine test) would dramatically improve the accuracy of tumor detection, reducing the risk of recurrence and progression of BCa. Moreover, intravesical instillation and systemic therapeutic strategies (cocktail therapy, immunotherapy, vaccine therapy, targeted therapy) also provide plentiful measures to break the predicament of BCa. Several exploratory clinical studies, including novel surgical approaches, pharmaceutical compositions, and bladder preservation techniques, emerged continually, which are supposed to be promising candidates for BCa clinical treatment. Here, recent advances and prospects of diagnosis, intravesical or systemic treatment, and novel drug delivery systems for BCa therapy are reviewed in this paper. |
format | Online Article Text |
id | pubmed-9265007 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92650072022-07-09 Advances in Diagnosis and Therapy for Bladder Cancer Hu, Xinzi Li, Guangzhi Wu, Song Cancers (Basel) Review SIMPLE SUMMARY: The clinical management of bladder cancer has been developing in the past decade, including diagnostic tools and treatment options. Both monotherapy and combination therapy have been undoubtedly upgraded. Multiple diagnostic techniques and therapeutic strategies have been developed to meet the urgent clinical needs, resulting in the emergence of various explorations for cancer diagnosis and therapy. In this review, we mainly focus on the advances in the diagnosis and treatment of bladder cancer. ABSTRACT: Bladder cancer (BCa) is one of the most common and expensive urinary system malignancies for its high recurrence and progression rate. In recent years, immense amounts of studies have been carried out to bring a more comprehensive cognition and numerous promising clinic approaches for BCa therapy. The development of innovative enhanced cystoscopy techniques (optical techniques, imaging systems) and tumor biomarkers-based non-invasive urine screening (DNA methylation-based urine test) would dramatically improve the accuracy of tumor detection, reducing the risk of recurrence and progression of BCa. Moreover, intravesical instillation and systemic therapeutic strategies (cocktail therapy, immunotherapy, vaccine therapy, targeted therapy) also provide plentiful measures to break the predicament of BCa. Several exploratory clinical studies, including novel surgical approaches, pharmaceutical compositions, and bladder preservation techniques, emerged continually, which are supposed to be promising candidates for BCa clinical treatment. Here, recent advances and prospects of diagnosis, intravesical or systemic treatment, and novel drug delivery systems for BCa therapy are reviewed in this paper. MDPI 2022-06-29 /pmc/articles/PMC9265007/ /pubmed/35804953 http://dx.doi.org/10.3390/cancers14133181 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hu, Xinzi Li, Guangzhi Wu, Song Advances in Diagnosis and Therapy for Bladder Cancer |
title | Advances in Diagnosis and Therapy for Bladder Cancer |
title_full | Advances in Diagnosis and Therapy for Bladder Cancer |
title_fullStr | Advances in Diagnosis and Therapy for Bladder Cancer |
title_full_unstemmed | Advances in Diagnosis and Therapy for Bladder Cancer |
title_short | Advances in Diagnosis and Therapy for Bladder Cancer |
title_sort | advances in diagnosis and therapy for bladder cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265007/ https://www.ncbi.nlm.nih.gov/pubmed/35804953 http://dx.doi.org/10.3390/cancers14133181 |
work_keys_str_mv | AT huxinzi advancesindiagnosisandtherapyforbladdercancer AT liguangzhi advancesindiagnosisandtherapyforbladdercancer AT wusong advancesindiagnosisandtherapyforbladdercancer |